GlassScriptPhysician profile
Scott Kizy
NPI 1497199715
$4,242.97
in general payments reported to CMS, 2019-2025
9 companies · $2,258 in 2025
The $2,258 reported for 2025 was more than what 83% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2021: $117 · 2022: $1,592 · 2023: $18.10 · 2024: $32.62 · 2025: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,228 · Education: $750 · Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,228.27 |
| Education | $750.00 |
| Food and Beverage | $330.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,453.62 | 2022-2025 | |
| Histosonics, INC. | $1,032.41 | 2025 | |
| Medtronic, INC. | $332.79 | 2021-2022 | |
| Covidien LP | $225.78 | 2019 | |
| Alcresta Therapeutics, INC. | $124.48 | 2022 | |
| Checkpoint Surgical, INC | $21.46 | 2024 | Checkpoint Stimulators |
| Ipsen Biopharmaceuticals, INC | $18.10 | 2023 | Tazverik |
| Novartis Pharmaceuticals Corporation | $17.85 | 2025 | |
| Tela Bio, INC. | $16.48 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kizy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.